Xencor executive sells shares worth 1.6 million
| XNCR Stock | USD 25.01 0.91 3.78% |
Slightly above 56% of all Xencor's retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Xencor Inc suggests that some traders are interested. Xencor's investing sentiment overview a quick insight into current market opportunities from investing in Xencor Inc. Many technical investors use Xencor Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Xencor |
Xencor executive sells shares worth 1.6 million
Read at investing.com
 |
Xencor Fundamental Analysis
We analyze Xencor's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xencor using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xencor based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Xencor is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Xencor Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xencor stock to make a market-neutral strategy. Peer analysis of Xencor could also be used in its relative valuation, which is a method of valuing Xencor by comparing valuation metrics with similar companies.
Peers
Xencor Related Equities
| REPL | Replimune | 35.11 | ||||
| PTGX | Protagonist Therapeutics | 11.55 | ||||
| KURA | Kura Oncology | 7.36 | ||||
| MLYS | Mineralys Therapeutics, | 5.22 | ||||
| ANAB | AnaptysBio | 5.20 | ||||
| KROS | Keros Therapeutics | 3.86 | ||||
| ERAS | Erasca | 3.85 | ||||
| ACLX | Arcellx | 3.69 | ||||
| SNDX | Syndax Pharmaceuticals | 3.14 | ||||
| MRUS | Merus BV | 2.55 | ||||
| NUVL | Nuvalent | 2.37 | ||||
| GLUE | Monte Rosa | 1.68 | ||||
| IDYA | Ideaya Biosciences | 0.71 | ||||
| EWTX | Edgewise Therapeutics | 0.69 | ||||
| LRMR | Larimar Therapeutics | 0.49 | ||||
| MGTX | MeiraGTx Holdings | 0.17 | ||||
| PCVX | Vaxcyte | 0.17 | ||||
| STRO | Sutro Biopharma | 0.79 | ||||
| VRDN | Viridian Therapeutics | 0.86 |
Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.